The result showed that the QQC group had an advantage in improving HMGB1 (MD: −4.34; 95% CI: −5.22 to −3.46; P < 10–6; AMSTAR 10; Evidence class IV) for patients with DCM (Figure 3) (Wei et al., 2022). The gene discussed is HMGB1; the disease is familial dilated cardiomyopathy.